NEW DELHI: India’s pharmaceutical industry must focus on both generics and innovative products, as well as develop products specially tailored for the country’s patient needs. Domestic companies ...
Eli Lilly's market share in India's weight‑loss drug market fell to 56% in March from 61% in February. Novo Nordisk's market share remained steady at 25%. Indian generic drugmakers have launched 26 ...
Generic dapagliflozin is indicated to lower heart failure hospitalization risk in type 2 diabetes with established cardiovascular disease or multiple risk factors, and to improve glycemic control ...
India is struggling with a rapid surge in type 2 diabetes and obesity. With the expiry of the patent for semaglutide, popularly known by the brand names Ozempic and WeGovy, and the entry of generic ...
The decision, based on a Commerce Department review, highlights supply risks while leaving room for future action on generic drug imports The United States will not impose tariffs on generic medicines ...
The wave of generic, locally made GLP-1 drugs that has flooded India within days of the patent lapse on Novo Nordisk’s Ozempic and Wegovy has sparked a price war and left regulators scrambling to ...
Concern that supply chain disruption could hit health essentials – and prices – from painkillers to cancer treatment Middle East crisis – live updates Britain is “a few weeks away” from medicine ...
Good morning, everyone, and welcome to our Viatris Investor event. I'm Bill Szablewski, Head of Capital Markets and Investor Relations. It's great to see everyone here in a full room today. Before we ...
India is launching cheap weight-loss drugs — but Novo Nordisk is betting its brands will stay on top
Novo lost semaglutide patent protection in India, triggering generic launches. Indian drugmakers launched generic versions at lower prices. Novo cut prices and used partnerships to defend market share ...
At least a dozen large Indian drugmakers are set to roll out copies of Novo Nordisk A/S’s blockbuster weight-loss drugs as soon as the patent expires Friday, crashing prices in the country with the ...
In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions. By Rebecca ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results